All of the patients with advanced lung adenocarcinoma in whom the diagnosis was made after April 1, 2008 were tested for EGFR mutations at the time of the diagnosis, whereas in the patients with other histological types of lung cancer, the testing was performed at the discretion of the attending physician. This evidence concerns the gene EGFR and lung carcinoma.